176 related articles for article (PubMed ID: 7946944)
21. Variable contribution of CYP2D6 to the N-dealkylation of S-(-)-propranolol by human liver microsomes.
Rowland K; Ellis SW; Lennard MS; Tucker GT
Br J Clin Pharmacol; 1996 Sep; 42(3):390-3. PubMed ID: 8877032
[TBL] [Abstract][Full Text] [Related]
22. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes.
Bloomer JC; Woods FR; Haddock RE; Lennard MS; Tucker GT
Br J Clin Pharmacol; 1992 May; 33(5):521-3. PubMed ID: 1388041
[TBL] [Abstract][Full Text] [Related]
23. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron.
Fischer V; Vickers AE; Heitz F; Mahadevan S; Baldeck JP; Minery P; Tynes R
Drug Metab Dispos; 1994; 22(2):269-74. PubMed ID: 8013282
[TBL] [Abstract][Full Text] [Related]
24. Regioselective hydroxylation of debrisoquine by cytochrome P4502D6: implications for active site modelling.
Lightfoot T; Ellis SW; Mahling J; Ackland MJ; Blaney FE; Bijloo GJ; De Groot MJ; Vermeulen NP; Blackburn GM; Lennard MS; Tucker GT
Xenobiotica; 2000 Mar; 30(3):219-33. PubMed ID: 10752638
[TBL] [Abstract][Full Text] [Related]
25. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.
Otton SV; Brinn RU; Gram LF
Drug Metab Dispos; 1988; 16(1):15-7. PubMed ID: 2894945
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of debrisoquin clearance in perfused rat livers and inhibition of dextromethorphan metabolism in human liver microsomes by 4-hydroxydebrisoquin or other metabolites of debrisoquin.
Jaruratanasirikul S; Cooper AD; Blaschke TF
Drug Metab Dispos; 1992; 20(3):379-82. PubMed ID: 1355711
[TBL] [Abstract][Full Text] [Related]
27. Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines.
Madani S; Paine MF; Lewis L; Thummel KE; Shen DD
Pharm Res; 1999 Aug; 16(8):1199-205. PubMed ID: 10468020
[TBL] [Abstract][Full Text] [Related]
28. Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine.
Muralidharan G; Cooper JK; Hawes EM; Korchinski ED; Midha KK
Eur J Clin Pharmacol; 1996; 50(1-2):121-8. PubMed ID: 8739822
[TBL] [Abstract][Full Text] [Related]
29. Interactions of bupranolol with the polymorphic debrisoquine/sparteine monooxygenase (CYP2D6).
Pressacco J; Muller R; Kalow W
Eur J Clin Pharmacol; 1993; 45(3):261-4. PubMed ID: 8276051
[TBL] [Abstract][Full Text] [Related]
30. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists.
Sanwald P; David M; Dow J
Drug Metab Dispos; 1996 May; 24(5):602-9. PubMed ID: 8723743
[TBL] [Abstract][Full Text] [Related]
31. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2.
Yoshimoto K; Echizen H; Chiba K; Tani M; Ishizaki T
Br J Clin Pharmacol; 1995 Apr; 39(4):421-31. PubMed ID: 7640150
[TBL] [Abstract][Full Text] [Related]
32. Propranolol hydroxylation and N-desisopropylation by cytochrome P4502D6: studies using the yeast-expressed enzyme and NADPH/O2 and cumene hydroperoxide-supported reactions.
Bichara N; Ching MS; Blake CL; Ghabrial H; Smallwood RA
Drug Metab Dispos; 1996 Jan; 24(1):112-8. PubMed ID: 8825198
[TBL] [Abstract][Full Text] [Related]
33. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.
Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA
Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590
[TBL] [Abstract][Full Text] [Related]
34. The metabolism of tamoxifen by human liver microsomes is not mediated by cytochrome P450IID6.
Blankson EA; Ellis SW; Lennard MS; Tucker GT; Rogers K
Biochem Pharmacol; 1991 Dec; 42 Suppl():S209-12. PubMed ID: 1768279
[No Abstract] [Full Text] [Related]
35. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily.
Rodrigues AD; Roberts EM; Mulford DJ; Yao Y; Ouellet D
Drug Metab Dispos; 1997 May; 25(5):623-30. PubMed ID: 9152603
[TBL] [Abstract][Full Text] [Related]
36. Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine.
Wang RW; Liu L; Cheng H
Drug Metab Dispos; 1996 Jul; 24(7):786-91. PubMed ID: 8818577
[TBL] [Abstract][Full Text] [Related]
37. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes.
Yasui-Furukori N; Hidestrand M; Spina E; Facciolá G; Scordo MG; Tybring G
Drug Metab Dispos; 2001 Oct; 29(10):1263-8. PubMed ID: 11560868
[TBL] [Abstract][Full Text] [Related]
38. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease.
Coleman T; Ellis SW; Martin IJ; Lennard MS; Tucker GT
J Pharmacol Exp Ther; 1996 May; 277(2):685-90. PubMed ID: 8627546
[TBL] [Abstract][Full Text] [Related]
39. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
[TBL] [Abstract][Full Text] [Related]
40. Competition between cytochrome P-450 isozymes for NADPH-cytochrome P-450 oxidoreductase affects drug metabolism.
Li DN; Pritchard MP; Hanlon SP; Burchell B; Wolf CR; Friedberg T
J Pharmacol Exp Ther; 1999 May; 289(2):661-7. PubMed ID: 10215637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
